Drug intelligence / Profile preview

AGN-242266

Development stage: Discontinued
Lead developer: AbbVie
Modality: Small Molecules
Administration: Oral, Sublingual, Subcutaneous, Intramuscular, Intravenous, Transdermal, Local, Rectal

Overview

AGN-242266 is a small molecule farnesoid X receptor (FXR) agonist that was developed for the treatment of nonalcoholic steatohepatitis (NASH). FXR is a nuclear receptor involved in bile acid regulation, lipid metabolism, and inflammation. By activating FXR, AGN-242266 was intended to reduce liver fat accumulation and fibrosis associated with NASH. The drug originated from Akarna Therapeutics and was later developed by Allergan and subsequently AbbVie following corporate acquisitions. It reached Phase 1 clinical development but has since been discontinued for NASH[2][3][1].

Other names: AGN 242266AGN242266AGN-242266AKN-083AKN083AKN 083

Targets

FXR (Farnesoid x-activated receptor)

Beyond the preview

Go deeper on AGN-242266.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGN-242266.

Explore the full profile